# Trastuzumab deruxtecan with pembrolizumab

Source: https://onco.cc/trials/nct04042701/  
OnCo record `nct04042701` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This early study combines trastuzumab deruxtecan with pembrolizumab in advanced breast or lung cancer. It studies a suitable dose, side effects and tumor response.

## Summary

This early study combines trastuzumab deruxtecan with pembrolizumab in advanced breast or lung cancer. It studies a suitable dose, side effects and tumor response.

Interventional study registered as NCT04042701, sponsored by Daiichi Sankyo. Registry phase: 1. Registry enrollment is 115 participants (estimated). Registry status checked October 10, 2026: active not recruiting. UCSF lists this study as closed to local enrollment; local availability and overall registry status are separate. See the registry for full eligibility and current sites.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-10-10
- Also known as: DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer
- Tags: ucsf-breast-coverage; interventional
- Registry id: NCT04042701
- Phase: 1
- Setting: Locally advanced or metastatic breast cancer or non-small cell lung cancer
- Sponsor: Daiichi Sankyo

## Sources

- ClinicalTrials.gov NCT04042701: https://clinicaltrials.gov/study/NCT04042701
- UCSF study listing and local availability: https://clinicaltrials.ucsf.edu/trial/NCT04042701

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Trastuzumab deruxtecan](https://onco.cc/drugs/trastuzumab-deruxtecan/)
- institutions: [UCSF Helen Diller Family Comprehensive Cancer Center](https://onco.cc/institutions/ucsf/)

---
JSON: https://onco.cc/api/v1/entities/nct04042701.json